Patents Assigned to Quest Diagnostics
  • Patent number: 9177766
    Abstract: Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: November 3, 2015
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Karin O. Thomassian
  • Publication number: 20150299811
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Application
    Filed: April 6, 2015
    Publication date: October 22, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • Publication number: 20150275277
    Abstract: Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene. The average expression of the 5? portion of the target gene is compared with the average expression of the 3? portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.
    Type: Application
    Filed: March 24, 2015
    Publication date: October 1, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Shih-Min Cheng
  • Publication number: 20150218627
    Abstract: The present invention provides methods of detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, the present invention provides advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples.
    Type: Application
    Filed: December 9, 2014
    Publication date: August 6, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Mansoor S. Mohammed, Natasa Dzidic, Christopher McCaskill, Jaeweon Kim
  • Patent number: 9097732
    Abstract: The invention relates to the detection of DHA and EPA. In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry and kits for carrying out such methods.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: August 4, 2015
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Scott M. Goldman, Julie A. Neidich
  • Publication number: 20150184222
    Abstract: Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample.
    Type: Application
    Filed: December 3, 2014
    Publication date: July 2, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Chen-Hsiung Yeh
  • Patent number: 9063119
    Abstract: Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: June 23, 2015
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Qibo Jiang, Richard E Reitz, Sum Chan
  • Patent number: 9057732
    Abstract: Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: June 16, 2015
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Amit Ghoshal, Nigel J. Clarke, Mildred M. Goldman
  • Patent number: 9046531
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: June 2, 2015
    Assignee: Quest Diagnostics Investments Inc.
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E Reitz
  • Patent number: 9034653
    Abstract: The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: May 19, 2015
    Assignee: Quest Diagnostics Investments Inc.
    Inventors: Brett Holmquist, Nigel Clarke
  • Patent number: 9012394
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: April 21, 2015
    Assignee: Quest Diagnostics Investments, Inc.
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Patent number: 8999634
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: April 7, 2015
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • Publication number: 20150080255
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 19, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Wanlong Ma, Maher Albitar
  • Patent number: 8969089
    Abstract: This disclosure provides methods for quantifying individual amino acids in various bodily fluids obtained from a human patient. Also provided are reference ranges for normal amino acid levels in the various bodily fluids (e.g., blood plasma, urine, cerebrospinal fluid, and saliva) and for various age groups (e.g., neonates, infants, children, and adults).
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: March 3, 2015
    Assignee: Quest Diagnostics Investments, Inc.
    Inventor: Scott Goldman
  • Patent number: 8963077
    Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: February 24, 2015
    Assignee: Quest Diagnostics Investments, Inc.
    Inventors: J. Fred Banks, Peter P. Chou, Noriya M. Matt
  • Publication number: 20150038367
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 5, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Patent number: 8936943
    Abstract: Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: January 20, 2015
    Assignee: Quest Diagnostics Investments, Inc.
    Inventors: Nigel J. Clarke, Brett Holmquist, Gloria Kwang-Ja Lee, Richard E. Reitz
  • Publication number: 20150004633
    Abstract: Provided are methods for diagnosing ovarian cancer or assessing the risk of developing ovarian cancer in a subject by measuring, in a biological sample from the subject, the amount of IL-6 and comparing the amount of IL-6 measured to a predetermined IL-6 cutoff value. Also provided are methods that further include measuring, in the biological sample, the amount of two or more biomarkers selected from the group consisting of transthyretin, apolipoprotein A1, transferrin, ?-2 microglobulin, and CA 125 II. The amount of IL-6 and biomarkers are useful in the diagnosis of ovarian cancer, and individuals can be identified as having ovarian cancer when the amount of IL-6 is greater than the IL-6 cutoff value and/or the biomarker score is greater than the biomarker score cutoff value.
    Type: Application
    Filed: September 26, 2012
    Publication date: January 1, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Kenneth Sisco, Peter Chou
  • Patent number: 8921062
    Abstract: Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: December 30, 2014
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Chen-Hsiung Yeh
  • Patent number: 8916680
    Abstract: Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 23, 2014
    Assignee: Quest Diagnostics Investments, Inc.
    Inventors: Cory E. Bystrom, Richard E Reitz